How Does Libtayo Work for Non-Small-Cell Lung Cancer (NSCLC)? Libtayo is a specific kind of medicine called immunotherapy. Immunotherapies work by helping your body’s own immune system work to ...

Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...

"With this approval, Libtayo becomes the first single-agent immunotherapy approved in Japan for the treatment of advanced cervical cancer." The MHLW approval is based on positive data from the ...

Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on ...

Specifically, the CHMP recommended the Libtayo combination be approved in the European Union (EU) for first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC ...

In the fourth quarter of 2024, Libtayo grew sales 50% to $367 million, propelling the PD-1 treatment past the blockbuster threshold for the first time. During the full year, the drug's sales reach ...

Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Regeneron Pharmaceuticals, Inc. Thu ...

Libtayo's revenue growth is impressive, with expectations to become a blockbuster, enhancing Regeneron's oncology presence. Regeneron benefits financially from Dupixent sales and a strong balance ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...

June 2 (Reuters) - Regeneron Pharmaceuticals (REGN.O), opens new tab said on Thursday it would buy the global rights to cancer drug Libtayo from French drugmaker Sanofi SA (SASY.PA), opens new tab ...

Sanofi will also receive an 11% royalty on global Libtayo sales. Sanofi's U.S.-listed shares rose 1.0% in premarket trading while Regeneron's stock is still inactive. The deal is expected to close ...